<p>/PRNewswire/ -- 泰格医药被评选为 “2025 年福布斯中国国际化旗舰品牌” 榜单上的 30 强公司之一，福布斯中国于周二宣布。</p>
<p>继续阅读</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null"/></p>
<p>福布斯中国于 2023 年推出国际化排名，以追踪扩展海外的公司。2025 年版引入了四个类别：<em>旗舰品牌、领先品牌、投资价值品牌和领军人物</em>——旗舰组由在国际市场上深耕的成熟大型公司组成。这些公司通常在海外生产、研发和运营方面进行投资，从出口导向的增长转向全球规模的管理。</p>
<p>泰格医药的入选展示了中国生物制药创新的全球影响力日益增强。作为全球临床开发服务提供商，泰格医药在北美、欧洲、中国、亚太、非洲和拉丁美洲等地运营着超过 180 个办公室和网络，员工超过 10,000 人。我们致力于构建一个集成的端到端平台，为医疗行业创造无限可能，并成为中国生物技术 “国际化” 战略的桥梁。</p>
<p>展望未来，泰格医药表示将继续扩大其全球足迹，加强本地化并加速数字化转型，以满足日益增长的国际需求。公司还旨在深化行业合作伙伴关系，推动中国制药创新，为全球患者提供更高质量、以研究为驱动的医疗解决方案。</p>
<p>有关 2025 年福布斯中国国际化系列 30&amp;30 的更多详情，请访问：https://mp.weixin.qq.com/s/xjdPLPfzZNZQhl3FPkJfaQ</p>
<p><strong>关于泰格医药</strong></p>
<p>泰格医药（股票代码：300347.SZ/3347.HK）是生物制药和医疗器械行业领先的综合研发解决方案提供商。我们提供广泛的服务组合，并承诺质量，从临床前开发到临床试验再到商业化，我们与超过 3,600 个客户合作，致力于高效、经济地推动他们的开发旅程。泰格医药目前在亚太、欧洲、北美、拉丁美洲和非洲拥有超过 180 个地点的全球网络，员工超过 10,000 人。我们致力于构建一个集成平台，为医疗行业创造无限可能，迎接挑战以履行我们服务未满足患者需求的承诺，最终拯救生命。了解更多信息，请访问 www.tigermedgrp.com。</p>
<p>来源：泰格医药</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMTA2Jk5ld3NJdGVtSWQ9Q04xNzU4NCZUcmFuc21pc3Npb25fSWQ9MjAyNTExMDYwNTA4UFJfTkVXU19VU1BSX19fX19DTjE3NTg0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMTA2Jk5ld3NJdGVtSWQ9Q04xNzU4NCZUcmFuc21pc3Npb25fSWQ9MjAyNTExMDYwNTA4UFJfTkVXU19VU1BSX19fX19DTjE3NTg0"/></p>

泰格医药

<p>泰格医药被评选为 “2025 年福布斯中国国际化旗舰品牌” 榜单中的 30 强公司之一。该排名由福布斯中国推出，旨在突出具有显著国际影响力的企业。泰格医药是一家全球临床开发服务提供商，在全球运营超过 180 个办公室，旨在增强其全球影响力和数字化转型，同时推动中国的药品创新。该公司与超过 3600 个客户合作，专注于生物制药领域的综合研发解决方案</p>

<p>, /PRNewswire/ -- Tigermed has been selected as one of the Top 30 companies on the &#34;2025 Forbes China Go-International Flagship Brands&#34; list, Forbes China announced Tuesday.</p>
<div class="lb-trans"><p>/PRNewswire/ -- 泰格医药被评选为 “2025 年福布斯中国国际化旗舰品牌” 榜单上的 30 强公司之一，福布斯中国于周二宣布。</p>
</div><p>Continue Reading</p>
<div class="lb-trans"><p>继续阅读</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null" alt="" original-src="https://www.prnewswire.com/news-releases/null"/></p>
<p>Forbes China launched the Go-International ranking in 2023 to track firms expanding overseas. The 2025 edition introduces four categories: <em>Flagship Brands, Leading Brands, Investment Value Brands and Leading Figures</em>—with the flagship group comprising large, mature companies with deeply established international footprints. These firms typically invest in overseas production, R&amp;D, and operations as they move from export-oriented growth to global-scale management.</p>
<div class="lb-trans"><p>福布斯中国于 2023 年推出国际化排名，以追踪扩展海外的公司。2025 年版引入了四个类别：<em>旗舰品牌、领先品牌、投资价值品牌和领军人物</em>——旗舰组由在国际市场上深耕的成熟大型公司组成。这些公司通常在海外生产、研发和运营方面进行投资，从出口导向的增长转向全球规模的管理。</p>
</div><p>Tigermed's selection demonstrates the growing global impact of China's biopharmaceutical innovation. As a global clinical development services provider, Tigermed operates more than 180 offices and networks worldwide with over 10,000 across North America, Europe, China, Asia-Pacific, Africa and Latin-America. We are devoted to building an integrated end-to-end platform that enables the boundless possibilities for the healthcare industry, and becoming a bridge for China biotech &#34;Go-International&#34; strategy.</p>
<div class="lb-trans"><p>泰格医药的入选展示了中国生物制药创新的全球影响力日益增强。作为全球临床开发服务提供商，泰格医药在北美、欧洲、中国、亚太、非洲和拉丁美洲等地运营着超过 180 个办公室和网络，员工超过 10,000 人。我们致力于构建一个集成的端到端平台，为医疗行业创造无限可能，并成为中国生物技术 “国际化” 战略的桥梁。</p>
</div><p>Looking ahead, Tigermed stated that it will continue to expand its global footprint, strengthen localisation and accelerate digital transformation to meet growing international demand. The company also aims to deepen industry partnerships to advance China's pharmaceutical innovation and deliver better quality, research-driven healthcare solutions to patients worldwide.</p>
<div class="lb-trans"><p>展望未来，泰格医药表示将继续扩大其全球足迹，加强本地化并加速数字化转型，以满足日益增长的国际需求。公司还旨在深化行业合作伙伴关系，推动中国制药创新，为全球患者提供更高质量、以研究为驱动的医疗解决方案。</p>
</div><p>For more details on the 2025 Forbes China Go-International series selection 30&amp;30, please visit: https://mp.weixin.qq.com/s/xjdPLPfzZNZQhl3FPkJfaQ</p>
<div class="lb-trans"><p>有关 2025 年福布斯中国国际化系列 30&amp;30 的更多详情，请访问：https://mp.weixin.qq.com/s/xjdPLPfzZNZQhl3FPkJfaQ</p>
</div><p><strong>About Tigermed</strong></p>
<div class="lb-trans"><p><strong>关于泰格医药</strong></p>
</div><p>Tigermed (Stock code: 300347.SZ/3347.HK) is a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry. With a broad portfolio of services and a promise of quality, from preclinical development to clinical trial to commercialization, we are collaborating with over 3,600 customers and committed to moving their development journey efficiently and cost-effectively. Tigermed currently represents a worldwide network of more than 180 locations with over 10,000 employees across Asia Pacific, Europe, North America, Latin America and Africa. We are devoted to building an integrated platform that enables the boundless possibilities for the healthcare industry, embracing challenges to fulfill our commitment to serving unmet patients' needs, and ultimately saving lives. Learn more at www.tigermedgrp.com.</p>
<div class="lb-trans"><p>泰格医药（股票代码：300347.SZ/3347.HK）是生物制药和医疗器械行业领先的综合研发解决方案提供商。我们提供广泛的服务组合，并承诺质量，从临床前开发到临床试验再到商业化，我们与超过 3,600 个客户合作，致力于高效、经济地推动他们的开发旅程。泰格医药目前在亚太、欧洲、北美、拉丁美洲和非洲拥有超过 180 个地点的全球网络，员工超过 10,000 人。我们致力于构建一个集成平台，为医疗行业创造无限可能，迎接挑战以履行我们服务未满足患者需求的承诺，最终拯救生命。了解更多信息，请访问 www.tigermedgrp.com。</p>
</div><p>SOURCE Tigermed</p>
<div class="lb-trans"><p>来源：泰格医药</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMTA2Jk5ld3NJdGVtSWQ9Q04xNzU4NCZUcmFuc21pc3Npb25fSWQ9MjAyNTExMDYwNTA4UFJfTkVXU19VU1BSX19fX19DTjE3NTg0" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=CN17584&amp;Transmission_Id=202511060508PR_NEWS_USPR_____CN17584&amp;DateId=20251106"/></p>

泰格医药入选 “2025 福布斯中国国际化旗舰品牌” 前 30 强